Skip to main content

SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System

SENIOR* Trial – Shortened DAPT** Regimen, Elderly Patients and SYNERGY Bioabsorbable Polymer (BP) Stent

SENIOR Trial is studying 1-month DAPT in stable elderly patients and 6-month DAPT in unstable elderly patients undergoing PCI with the SYNERGY BP-DES or REBEL™ BMS. 

Fast Facts Sign Up
icon_document.png

Indications, Safety, and Warnings

 icon-send-questions.png

Frequently Asked Questions

 icon-contact-email

Request a Sales Rep

Trial Design

Multicenter, randomized trial studying 1,200 patients age 75 or older with coronary artery disease; 596 received a SYNERGY BP-DES and 605 received a REBEL BMS.
 

Nearly identical DAPT duration in both arms of the study1

Nearly identical DAPT duration in both arms of the study
 

Safety and Primary endpoint: MACCE at 12 months data

The SYNERGY BP-DES showed Superior results versus REBEL BMS in elderly patients that received a shortened DAPT regimen in the SENIOR Trial at 12 months1

All Patients

  • 29% reduction in MACCE with SYNERGY BP-DES1
  • 70% reduction (More than 3X reduction) in ID-TLR with SYNERGY BP-DES1
  • The SYNERGY BP-DES continued to show exceptionally low ARC Def/Prob stent thrombosis (ST) rate of 0.5% (versus 1.4% with BMS, p=0.13)1

1-Month DAPT Discontinuation Cohort

  • More than 50% of patients received 1-month DAPT
  • Zero ST with SYNERGY BP-DES after patient stopped DAPT at 1-month through 12-months1
  • 34% reduction in MACCE with SYNERGY BP-DES2
  • 90% reduction (More than 10X reduction) in ID-TLR with SYNERGY BP-DES2
SENIOR Trial Safety Data with SYNERGY BP-DES in 1-Month DAPT Cohort - Primary Endpoint: MACCE at 12-months
 

Safety and MACCE at 2-Year data

SYNERGY BP-DES showed statistically significant reduction in ID-TLR compared to REBEL BMS at 2-Years3

All Patients

  • 65% reduction (Nearly 3X reduction) in ID-TLR with SYNERGY BP-DES
  • The SYNERGY BP-DES continued to show low ARC Def/Prob stent thrombosis (ST) rate of 0.7% (versus 1.4% with BMS, p=0.28)
Safety Endpoints at 12-months

1-Month DAPT Discontinuation Cohort

  • 79% reduction (More than 4.5X reduction) in ID-TLR with SYNERGY BP-DES
  • The SYNERGY BP-DES continued to show exceptionally low ARC Def/Prob stent thrombosis (ST) rate of 0.6% (versus 1.4% with BMS, p=0.32)
1-Month DAPT Discontinuation Cohort
Clinical Outcomes

Clinical Outcomes

Outstanding evidence across trials

Button
Real-World Studies

Real-World Studies

Low event rates in real-world studies

Button
Early Healing

Early Healing

Advanced design for optimal healing

Button
Top